Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis

被引:4
|
作者
Fiorica, Francesco [1 ]
Buttigliero, Consuelo [2 ]
Grigolato, Daniela [1 ]
Muraro, Marco [1 ]
Turco, Fabio [2 ]
Munoz, Fernando [3 ]
Tucci, Marcello [4 ]
机构
[1] AULSS 9 Scaligera, Dept Radiat Oncol & Nucl Med, I-37045 Verona, Italy
[2] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, I-10093 Turin, Italy
[3] Hosp Aosta, Radiat Oncol TomoTherapy Ctr, I-11000 Aosta, Italy
[4] Cardinal Massaia Hosp, Dept Med Oncol, I-14100 Asti, Italy
关键词
triplet therapy; hormone-sensitive prostate cancer; high volume metastatic disease; de novo metastatic disease; systematic review; metanalysis; INCREASED SURVIVAL; OPEN-LABEL; ENZALUTAMIDE; ABIRATERONE; MITOXANTRONE; METAANALYSIS; PREDNISONE; RESISTANCE; MECHANISMS; FLUTAMIDE;
D O I
10.3390/curroncol29120747
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, significant changes have occurred in metastatic hormone-sensitive prostate cancer (mHSPC) management, where docetaxel and new androgen receptor pathway inhibitors (ARPI) have been shown to improve overall survival (OS) compared to androgen deprivation therapy (ADT). Recent data could once again radically change mHSPC treatment. PEACE-1 and ARASENS trials demonstrated a survival benefit of the addition of ARPI to docetaxel and ADT combination (triplet therapy), compared to docetaxel and ADT. With multiple options to choose from, it is crucial to identify the patients who would benefit most from triplet therapy. In this meta-analysis, we evaluated the activity of the triplet therapy versus docetaxel plus ADT in mHSPC. A systematic review of PubMed/Medline, Embase, and the proceedings of major international meetings was performed. Five RCTs fulfilled the inclusion criteria. PEACE-1 and ARASENS studies reported disease-free survival (DFS) and OS. Post hoc analysis of three other trials evaluated the combination of ARPI, docetaxel and ADT. Globally, 2538 patients were included (1270 triplet therapy; 1268 docetaxel + ADT). Triplet therapy was associated with improved OS (hazard ratio (HR) 0.74; 95% confidence interval (CI), 0.66-0.83, p < 0.00001). A statistically significant benefit was shown in high-volume mHSPC patients (HR 0.76; 95% CI 0.59-0.97, p = 0.03) and in patients with de novo metastatic disease (HR 0.73; 95% CI, 0.64-0.82, p < 0.00001). The addition of ARPI to standard therapy was associated with DFS improvement (HR 0.41; 95% CI, 0.35-0.49, p < 0.00001). This metanalysis shows a significant OS benefit from concomitant administration of ARPI, docetaxel and ADT in high volume and de novo mHSPC.
引用
收藏
页码:9511 / 9524
页数:14
相关论文
共 50 条
  • [1] Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
    Yanagisawa, Takafumi
    Rajwa, Pawel
    Thibault, Constance
    Gandaglia, Giorgio
    Mori, Keiichiro
    Kawada, Tatsushi
    Fukuokaya, Wataru
    Shim, Sung Ryul
    Mostafaei, Hadi
    Motlagh, Reza Sari
    Quhal, Fahad
    Laukhtina, Ekaterina
    Pallauf, Maximilian
    Pradere, Benjamin
    Kimura, Takahiro
    Egawa, Shin
    Shariat, Shahrokh F.
    [J]. EUROPEAN UROLOGY, 2022, 82 (06) : 584 - 598
  • [2] Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
    Maiorano, B. A.
    De Giorgi, U.
    Roviello, G.
    Messina, C.
    Altavilla, A.
    Cattrini, C.
    Mennitto, A.
    Maiello, E.
    Di Maio, M.
    [J]. ESMO OPEN, 2022, 7 (05)
  • [3] Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
    Tucci, Marcello
    Bertaglia, Valentina
    Vignani, Francesca
    Buttigliero, Consuelo
    Fiori, Cristian
    Porpiglia, Francesco
    Scagliotti, Giorgio Vittorio
    Di Maio, Massimo
    [J]. EUROPEAN UROLOGY, 2016, 69 (04) : 563 - 573
  • [4] Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population
    Gupta, Alok
    Hussain, Shaik Maheboob
    Sonthwal, Neha
    Chaturvedi, Harit
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (02) : 389 - 392
  • [5] Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
    Roy, Soumyajit
    Sayyid, Rashid
    Saad, Fred
    Sun, Yilun
    Lajkosz, Katherine
    Ong, Michael
    Klaassen, Zachary
    Malone, Shawn
    Spratt, Daniel E.
    Wallis, Christopher J. D.
    Morgan, Scott C.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 494 - 502
  • [6] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [7] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer
    Boegemann, Martin
    [J]. UROLOGIE, 2023, 62 (04): : 354 - 359
  • [8] The Addition of Darolutamide to Androgen Deprivation Therapy and Docetaxel in a 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
    Crawford, David
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07)
  • [9] Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer
    Wenzel, Mike
    Hoeh, Benedikt
    Chun, Felix K. H.
    Mandel, Philipp
    [J]. UROLOGIE, 2023, 62 (04): : 360 - 368
  • [10] EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES OF DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E388 - E389